SPIMACO acquires 48% of EirGen Ireland:

24/03/2012 Argaam

SPIMACO Pharmaceutical Company announced today on tadawul acquiring 48% interest in EirGen pharma Ltd.; An Irish company in the business of producing and developing High Potency Cytotoxic Pharmaceutical Products.

The deal is valued at EUR 19m equivalent to SAR 93m and is financed by the company’s internal resources.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.